| Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... Nature medicine 27 (10), 1752-1760, 2021 | 448 | 2021 |
| Activate: randomized clinical trial of BCG vaccination against infection in the elderly EJ Giamarellos-Bourboulis, M Tsilika, S Moorlag, N Antonakos, A Kotsaki, ... Cell 183 (2), 315-323. e9, 2020 | 332 | 2020 |
| Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis E Kyriazopoulou, K Leventogiannis, A Norrby-Teglund, G Dimopoulos, ... BMC medicine 15, 1-10, 2017 | 169 | 2017 |
| An open label trial of anakinra to prevent respiratory failure in COVID-19 E Kyriazopoulou, P Panagopoulos, S Metallidis, GN Dalekos, G Poulakou, ... Elife 10, e66125, 2021 | 160 | 2021 |
| Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis E Kyriazopoulou, T Huet, G Cavalli, A Gori, M Kyprianou, P Pickkers, ... The Lancet Rheumatology 3 (10), e690-e697, 2021 | 143 | 2021 |
| Coronavirus disease 2019 as cause of viral sepsis: a systematic review and meta-analysis E Karakike, EJ Giamarellos-Bourboulis, M Kyprianou, ... Critical care medicine 49 (12), 2042-2057, 2021 | 132 | 2021 |
| Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial E Kyriazopoulou, L Liaskou-Antoniou, G Adamis, A Panagaki, ... American Journal of Respiratory and Critical Care Medicine 203 (2), 202-210, 2021 | 100 | 2021 |
| The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort E Karakike, E Kyriazopoulou, I Tsangaris, C Routsi, JL Vincent, ... Critical care 23, 1-8, 2019 | 96 | 2019 |
| Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial K Leventogiannis, E Kyriazopoulou, N Antonakos, A Kotsaki, I Tsangaris, ... Cell Reports Medicine 3 (11), 2022 | 43 | 2022 |
| BioFire® FilmArray® Pneumonia Panel for Severe Lower Respiratory Tract Infections: Subgroup Analysis of a Randomized Clinical Trial E Kyriazopoulou, A Karageorgos, L Liaskou-Antoniou, P Koufargyris, ... Infectious Diseases and Therapy 10, 1437-1449, 2021 | 23 | 2021 |
| Antimicrobial stewardship using biomarkers: Accumulating evidence for the critically ill E Kyriazopoulou, EJ Giamarellos-Bourboulis Antibiotics 11 (3), 367, 2022 | 21 | 2022 |
| International Collaborative Group for Anakinra in COVID-19. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis E Kyriazopoulou, T Huet, G Cavalli, A Gori, M Kyprianou, P Pickkers, ... Lancet Rheumatol 3 (10), e690-e697, 2021 | 21 | 2021 |
| Survival benefit associated with clarithromycin in severe community-acquired pneumonia: a matched comparator study E Kyriazopoulou, D Sinapidis, S Halvatzis, D Velissaris, N Alexiou, ... International journal of antimicrobial agents 55 (1), 105836, 2020 | 20 | 2020 |
| Angiopoietin-2 levels as predictors of outcome in mechanically ventilated patients with acute respiratory distress syndrome I Tsangaris, A Tsantes, E Vrigkou, P Kopterides, A Pelekanou, K Zerva, ... Disease Markers 2017, 2017 | 20 | 2017 |
| Imported Chikungunya fever case in Greece in June 2014 and public health response S Tsiodras, D Pervanidou, E Papadopoulou, D Kavatha, A Baka, ... Pathogens and Global Health 110 (2), 68-73, 2016 | 14 | 2016 |
| Author correction: early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... Nature Medicine 27 (10), 1850-1850, 2021 | 12 | 2021 |
| Monitoring immunomodulation in patients with sepsis E Kyriazopoulou, EJ Giamarellos-Bourboulis Expert Review of Molecular Diagnostics 21 (1), 17-29, 2021 | 12 | 2021 |
| Biomarkers in sepsis: can they help improve patient outcome? E Kyriazopoulou, G Poulakou, EJ Giamarellos-Bourboulis Current opinion in infectious diseases 34 (2), 126-134, 2021 | 11 | 2021 |
| Anakinra to prevent respiratory failure in COVID-19 E Kyriazopoulou, P Panagopoulos, S Metallidis, GN Dalekos, G Poulakou, ... medRxiv, 2020.10. 28.20217455, 2020 | 8 | 2020 |
| Early anakinra treatment for COVID-19 guided by urokinase plasminogen receptor E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... medRxiv, 2021.05. 16.21257283, 2021 | 7 | 2021 |
